Sorrento is an investment vehicle powered by 3 engines. Covid, cancer and non-opioid pain. All 3 engines are working and are powerful!
COVISTIX leads the way for Covid products.
SEMDEXA leads the way for pain products.
ABIVERTINIB leads the way for cancer products.
All 3 products have large blockbuster potential and all 3 are followed by other large potential products.
COVISTIX sales can pave the way for ABIVERTINIB(ARDS), COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS.
SEMDEXA sales can pave the way for SP-103, SP-104, RTX(cancer pain), and RTX(arthritic pain).
ABIVERTINIB can pave the way for a dozen ADNAB(Mayo Clinic drugs, a dozen DAR-T drugs and various other ADC's and an oncolytic virus.
Sorrento is not a one trick pony.